Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -4.33%21 EBITDA Margin % is 9.72% as of Sep. 2025, which is 31% below its 10-year median of 14.01. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 117 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 66.67% on this metric.
Cellyan Biotechnology Co (NAS:HKPD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cellyan Biotechnology Co EBITDA Margin % Related Terms
Cellyan Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKPD vs COSM, SNYR, YI: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a EBITDA Margin % of 9.72% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cellyan Biotechnology Co and its competitors. This is 31% below median its historical median of 14.01. Over the past decade, Cellyan Biotechnology Co's EBITDA Margin % has ranged from 2.63 to 15.18. According to the industry distribution chart, Cellyan Biotechnology Co ranks #78 out of 117 companies in the Medical Distribution industry, placing it in the top 66.7%.
Is Cellyan Biotechnology Co's EBITDA Margin % too high?
Cellyan Biotechnology Co's current EBITDA Margin % of 9.72% is 31% below median its 10-year median of 14.01. Over the past 10 years, this metric has ranged from a low of 2.63 to a high of 15.18. The Medical Distribution industry median EBITDA Margin % is 4.20. Cellyan Biotechnology Co's value of 9.72% is 131.4% above this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #78 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's EBITDA Margin % compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #78 out of 117 companies for EBITDA Margin %. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median EBITDA Margin % is 4.20. Cellyan Biotechnology Co's value of 9.72% is 131.4% above this benchmark. Historically, Cellyan Biotechnology Co's own EBITDA Margin % has ranged from 2.63 to 15.18 over the past decade. While the company's 10-year median is 14.01 vs. the industry median of 4.20, Cellyan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.20, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current EBITDA Margin % of 9.72% is 131.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current EBITDA Margin % is 9.72%, which is 31% below median its own 10-year median of 14.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current EBITDA Margin % of 9.72%. The current EBITDA Margin % is 9.72%, which is 31% below median its 10-year median of 14.01 and 131.4% above the Medical Distribution industry median of 4.20. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current EBITDA Margin % is 9.72% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
